Eglin c based drugs for treatment of disease
US7001884B2 · kind B2 · utility
16Cited by
7References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 17, 2002 |
| Grant date | Feb 21, 2006 |
| Priority date | — |
| Expiry date | Aug 20, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/58
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to eglin c variants which inhibit proteases, and in particular to eglin c mutants at adventitious contact sites. The present invention also relates to eglin c variants which comprise mutations in both adventitious contact sites and at reactive loop sites. The present invention further relates to methods of preparing the eglin c variants, and methods of using the eglin c variants for treatment of diseases including acute bacterial, viral, and fungal infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.